ABSTRACT
In 2020, CMS updated the ‘Final Rule’ for organ procurement organizations (OPO) in 2020 to include new metrics of OPO performance with a carveout whereby pancreata procured for research count as a “donor” to reward OPOs procuring pancreata for islet cell research or transplantation. Yet data suggested OPOs took advantage of this loophole, leading to updated guidance in 2024 to require OPOs classify whether procured research pancreata were “accepted for islet cell research.” Based on updated data using the new CMS codes, the increase in research pancreas procurement was nearly half previously reported, but far greater than prior to 2020. Importantly, the number of pancreata OPOs reported were accepted for islet cell research were an order of magnitude greater than what was used by the Integrated Islet Cell Distribution Program (IIDP) and the Network for Pancreatic Organ Donors with Diabetes (nPOD), the two largest sources of islet cell/pancreata for qualified researchers in the US. Inappropriate procurement of organs, and mislabeling them as being used for “islet cell research” raises questions of fraud, waste, and abuse that requires further investigation and transprancy.
INTRODUCTION
The Centers for Medicare and Medicaid Services (CMS) updated the ‘Final Rule’ for organ procurement organizations (OPO) in 2020 to include new metrics of OPO performance with a carveout whereby pancreata procured for research count as a “donor” to reward OPOs procuring pancreata for islet cell research or transplantation.1 Yet data suggested OPOs took advantage of this loophole,2 leading to congressional inquiries. CMS updated its guidance in 2024 to require OPOs classify whether procured research pancreata were “accepted for islet cell research…for use in bona fide research conducted by a qualified researcher, such as those approved by the National Institutes of Health.” 3 We sought to evaluate changes in pancreas research procurement based on updated coding and compare these to publicly available data on pancreas and islet cell research.
METHODS
We conducted a retrospective cohort study following the STROBE reporting guidelines. We evaluated Organ Procurement and Transplantation Network (OPTN) data of reported research pancreata from 1/1/2018-12/31/2024. We compared these OPO-reported data to publicly available data from the Integrated Islet Cell Distribution Program (IIDP)4,5 and the Network for Pancreatic Organ Donors with Diabetes (nPOD).6
RESULTS
Based on updated OPTN data, the increase in research pancreas procurement began in 2022, rather than 2021 (Figure 1a),2 and was nearly half previously reported. From 2018-2021, OPOs reported procuring pancreata for islet cell research that was 6-10 times higher than those isolated by the IIDP.5 Yet from 2022-2024, this discrepancy grew to a 20-30 fold difference, despite the IIDP adding centers (Table 1).4,5 Since 2007, nPOD utilized pancreata from 688 donors, one-third the number of pancreata OPOs reported were accepted for islet cell research in just 2024.
(four panels): Data on pancreata reported as procured for research purposes a. Figure 1a: Annual data on research pancreas procurement and IIDP islet cells before and after the new CMS guidance; 2018-2023 b. Figure 1b: OPO-level data on changes in reported research pancreas procurements in 2021 c. Figure 1c: OPO-level data on changes in reported research pancreas procurements in 2022 d. Figure 1d: OPO-level data on changes in reported research pancreas procurements in 2023
The changes in reporting of research pancreata was variable across OPOs, with half of the highest-procuring OPOs revising their data to report only limited pancreata procured for research, while the other half continued to report disproportionately high numbers of procured research pancreata (Figures 2b-2d, eTable 1). In 2024, procured research pancreata were concentrated in 8 OPOs, who reported collecting 1,551 pancreata “accepted for islet” cell research, 75.6% of national data. However, the IIDP, with its 10 islet cell isolation centers, only collected 45 pancreata for islet cell isolates from these OPOs (Table 1).5
DISCUSSION
The CMS guidance on OPO reporting of research pancreata procurements attenuated the reported growth in research pancreata.2 Yet there continues to be a dramatic increase in the number of pancreata reportedly procured for research, concentrated among 8 OPOs. Despite inquiries from the Senate Finance Committee, the disposition of these islet cells remains unclear.
Allo-islet cell transplantation, overseen by the Food and Drug Administration, remains rare (<50 cases/year). And despite the IIDP expanding from 5 to 10 isolation centers,4,5 OPOs report a more than 20-fold higher procurement of islet cells for research than what was used by the IIDP, with even greater differences in some OPOs. Islet cell isolation is costly and requires specialized equipment, and there are a limited number of isolation centers, with the leading centers in the IIDP.4,5 During this same period, nPOD reported 688 pancreata used for research (38 per year). Therefore, combining the totals from the IIDP and nPOD, there is more than a 10-fold difference in the number of pancreata OPOs report are accepted by qualified researchers, compared to what is used by the two largest pancreata/islet cell research networks in the US. Procurement of research pancreata uses taxpayer dollars, and involves procuring organs from deceased donors. Inappropriate procurement of organs, and mislabeling them as being used for “islet cell research” raises questions of fraud, waste, and abuse that requires further investigation and transprancy.
Data Availability
The OPTN data are available by request from the OPTN, which were made available in aggregate data per OPO per year, and due to the DUA require other investigators request the data from the OPTN. the IIDP data are available on the IIDP website: https://iidp.coh.org/Overview/Program-Statistics
Figures and Figure Legends
Acknowledgments
This work was supported in part by Health Resources and Services Administration contract HHSH250-2019-00001C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Data on islet cell research from the IIDP were obtained from publicly available data online from the IIDP. The opinions and perspectives of these data are our own. Dr. Goldberg and Erin Tewksbury had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. There was no funding organization or sponsor involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Abbreviations
- (CMS)
- Centers for Medicare and Medicaid Services
- (OPOs)
- Organ procurement organizations
- (OPTN)
- Organ Procurement and Transplantation Network
- (IIDP)
- Integrated Islet Cell Distribution Program
- (nPOD)
- Network for Pancreatic Organ Donors with Diabetes
